Enlivex Therapeutics (NASDAQ:ENLV) Announces Earnings Results

Enlivex Therapeutics (NASDAQ:ENLV) announced its quarterly earnings results on Monday. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.07), Zacks reports.

Enlivex Therapeutics Trading Down 1.4 %

Shares of Enlivex Therapeutics stock traded down $0.01 during trading hours on Wednesday, reaching $0.94. 28,763 shares of the company’s stock were exchanged, compared to its average volume of 154,250. The firm has a market capitalization of $20.06 million, a price-to-earnings ratio of -0.96 and a beta of 1.11. The company has a fifty day moving average of $1.09 and a 200-day moving average of $1.23. Enlivex Therapeutics has a 52-week low of $0.81 and a 52-week high of $4.59.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. HC Wainwright boosted their price target on shares of Enlivex Therapeutics from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, March 24th. D. Boral Capital reaffirmed a “buy” rating and issued a $13.00 target price on shares of Enlivex Therapeutics in a report on Monday, March 3rd.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial.